Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
about
Understanding the priorities for women diagnosed with lymphangioleiomyomatosis: a patient perspectiveDoxycycline use in patients with lymphangioleiomyomatosis: biomarkers and pulmonary function response.Serum VEGF-D a concentration as a biomarker of lymphangioleiomyomatosis severity and treatment response: a prospective analysis of the Multicenter International Lymphangioleiomyomatosis Efficacy of Sirolimus (MILES) trialWomen with TSC: Relationship between Clinical, Lung Function and Radiological Features in a Genotyped Population Investigated for Lymphangioleiomyomatosis.Lymphangioleiomyomatosis: current and future.Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis modelEPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.Cystic lung disease.Lymphangioleiomyomatosis: New Treatment Perspectives.Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.Matrix metalloproteinases -8 and -9 in the Airways, Blood and Urine During Exacerbations of COPD.Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Reply: The ATS/JRS Guidelines on Lymphangioleiomyomatosis: Filling in the Gaps.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Emerging biomarkers of lymphangioleiomyomatosis.Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.
P2860
Q28596632-F4B61BFF-6A44-454E-BE33-338692470149Q33823877-0018E398-0EBB-4E39-9AA2-C7A990A74A61Q34380247-851AD3EF-5F5A-4A0A-95A2-CF35172CD721Q36015287-76B5248E-AA22-4D00-B3D6-2C22281E5C1FQ36542254-6A05FF8A-300F-4BB9-9D67-88F800F3E7D4Q37193373-BBB8900F-0971-4CC1-A60C-98826265B041Q37397803-6119E4AE-2DEE-41D1-8B40-1A322891BB32Q38111303-4BA31174-94D2-4D45-877D-C8199D0E2B21Q38484497-0E451680-C6FB-4698-A94C-5B7FDD41387BQ38895095-3A7CC933-713D-4746-9DF1-3E28657C7816Q46662378-F4C67DED-A572-4A43-B157-CBFC1BCDB54BQ47370738-B4DE97F6-686A-459C-BF66-F55F0896E978Q48134309-F5DD8003-3353-462E-9B4D-E1533789AE97Q48355779-F42851C1-E6DA-4E39-925F-EC738C351B4DQ49679457-960E599D-E81E-465B-A0FB-FEB7FA634FB9Q50630588-97B571EE-2668-41A0-B337-3BED01A2E751
P2860
Clinical utility of diagnostic guidelines and putative biomarkers in lymphangioleiomyomatosis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@ast
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@en
type
label
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@ast
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@en
prefLabel
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@ast
Clinical utility of diagnostic ...... s in lymphangioleiomyomatosis.
@en
P2093
P2860
P50
P356
P1433
P1476
Clinical utility of diagnostic ...... rs in lymphangioleiomyomatosis
@en
P2093
Kate S Pointon
Maruti Kumaran
William Y C Chang
P2860
P2888
P356
10.1186/1465-9921-13-34
P577
2012-04-18T00:00:00Z
P5875
P6179
1003517066